BioSpace News Archive

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program.

Tectonic Therapeutic today announced that Dr. Marcella (“Marcie”) Ruddy, MD has been appointed Chief Medical Officer.

Seres Therapeutics, Inc. today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC).

Glaukos Corporation announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held July 23–27, 2021 in Las Vegas, Nevada.

Premia Spine today announced a growing foundation of clinical and economic evidence supporting its TOPS facet arthroplasty system,

Humacyte, Inc. today announces that Laura Niklason, M.D., Ph.D., Chief Executive Officer, delivered an invited presentation on laboratory and preclinical findings and notable criteria for engineering functional air sacs in the lungs, which support the potential to create engineered lung tissue organ, at the virtual Janelia R3 – Replace, Repair, Regenerate Planning Workshop.

Titan Medical Inc. today announced that David McNally, President and CEO of Titan Medical, and Stephen Lemieux, Chief Financial Officer, will be meeting with investors during the Alliance Global Partners Virtual MedTech Summer Investor Conference on Thursday, July 29, 2021.

ZYUS Life Sciences Inc. announced today that its wholly owned U.S. subsidiary, ZYUS Life Sciences U.S. Ltd. has received one patent allowance notification and two patent issuances from the United States Patent and Trademark Office (USPTO).

Eisai Inc. announced today the presentation of findings from the company’s robust Alzheimer’s disease (AD) pipeline, including lecanemab (BAN2401).

Adagene Inc. today announced that it has entered into the clinical trial collaboration and supply agreement with Merck (known as “MSD” outside the United States and Canada), the leader among top immuno-oncology (IO) drugs on the market.